FDA Oncology Announcements

Anti-VEGFR × Thoracic × Clear all

3 Announcements

FDA approves ramucirumab plus erlotinib for first-line metastatic NSCLC

Trial: RELAY
Drugs: CYRAMZA (ramucirumab) · Anti-VEGFR antibody, erlotinib · EGFR inhibitor
Condition: Thoracic

FDA approves ramucirumab plus erlotinib for first-line metastatic NSCLC

Trial: RELAY
Drugs: CYRAMZA (ramucirumab) · Anti-VEGFR antibody, erlotinib · EGFR inhibitor
Condition: Thoracic

Ramucirumab (Cyramza)

Drugs: Cyramza (ramucirumab) · Anti-VEGFR antibody, docetaxel · Taxane, paclitaxel · Taxane
Condition: Thoracic